• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于多发性骨髓瘤诊断和监测的新工具。

New tools for diagnosis and monitoring of multiple myeloma.

作者信息

San-Miguel Jesús F, Paiva Bruno, Gutiérrez Norma C

机构信息

From the Hospital Universitario de Salamanca, Salamanca, Spain; IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain.

出版信息

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e313.

DOI:10.14694/EdBook_AM.2013.33.e313
PMID:23714534
Abstract

This article reviews the most relevant techniques currently used for the evaluation of patients with multiple myeloma. Although bone marrow morphologic examination and electrophoretic analysis of the monoclonal paraprotein and conventional x-rays remain the "gold standard" techniques for fast, accurate, and cost-effective diagnosis, other assays such as molecular cytogenetics, immunophenotyping, MRI, and PET-CT may contribute to a better assessment of patients with myeloma. Here, we will discuss not only the contribution of each technique to differential diagnosis of monoclonal gammopathies, but also the value of each parameter for determining prognosis and for monitoring treatment efficacy. In addition, possible technical pitfalls inherent to each technique will be analyzed.

摘要

本文综述了目前用于评估多发性骨髓瘤患者的最相关技术。尽管骨髓形态学检查、单克隆副蛋白的电泳分析和传统X线检查仍是快速、准确且经济高效诊断的“金标准”技术,但其他检测方法,如分子细胞遗传学、免疫表型分析、MRI和PET-CT,可能有助于更好地评估骨髓瘤患者。在此,我们不仅将讨论每种技术对单克隆丙种球蛋白病鉴别诊断的贡献,还将讨论每个参数在确定预后和监测治疗疗效方面的价值。此外,还将分析每种技术固有的可能技术缺陷。

相似文献

1
New tools for diagnosis and monitoring of multiple myeloma.用于多发性骨髓瘤诊断和监测的新工具。
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e313.
2
Conventional diagnostics in multiple myeloma.多发性骨髓瘤的传统诊断方法。
Eur J Cancer. 2006 Jul;42(11):1510-9. doi: 10.1016/j.ejca.2005.11.039. Epub 2006 Jun 9.
3
Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis.单克隆丙种球蛋白病:诊断与预后临床问题的新方法
Blood Rev. 1989 Dec;3(4):222-36. doi: 10.1016/0268-960x(89)90030-1.
4
Measurable disease evaluation in patients with myeloma.多发性骨髓瘤患者的可测量疾病评估。
Best Pract Res Clin Haematol. 2020 Mar;33(1):101154. doi: 10.1016/j.beha.2020.101154. Epub 2020 Feb 4.
5
CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy.基于达雷妥尤单抗的化疗后多发性骨髓瘤患者出现CD38阴性复发
Eur J Haematol. 2017 Aug;99(2):186-189. doi: 10.1111/ejh.12902. Epub 2017 Jun 6.
6
CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features.CD117 在浆细胞疾病中的表达与骨髓和淋巴造血细胞发育成熟改变以及有利的疾病特征相关。
Haematologica. 2011 Feb;96(2):328-32. doi: 10.3324/haematol.2010.031872. Epub 2010 Oct 22.
7
Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.微小 RNA 在多发性骨髓瘤的诊断、预后和治疗中的作用。
Int J Mol Sci. 2020 Oct 13;21(20):7539. doi: 10.3390/ijms21207539.
8
Application and pitfalls of immunophenotyping in challenging plasma cell neoplasms: A case series.免疫表型分析在疑难浆细胞肿瘤中的应用及陷阱:病例系列。
Hum Pathol. 2024 Aug;150:86-96. doi: 10.1016/j.humpath.2024.06.012. Epub 2024 Jun 21.
9
expressing CD14CD16 monocytes expand in multiple myeloma patients leading to increased osteoclasts.表达CD14CD16的单核细胞在多发性骨髓瘤患者中增多,导致破骨细胞增加。
Haematologica. 2017 Apr;102(4):773-784. doi: 10.3324/haematol.2016.153841. Epub 2017 Jan 5.
10
Detection of minimal residual disease.微小残留病的检测
Methods Cell Biol. 2001;64:385-420. doi: 10.1016/s0091-679x(01)64023-8.

引用本文的文献

1
Multiple myeloma inhibitory effects of natural compounds: enhancement through nanoparticle carriers.天然化合物对多发性骨髓瘤的抑制作用:通过纳米颗粒载体增强。
Front Pharmacol. 2025 Jun 17;16:1589090. doi: 10.3389/fphar.2025.1589090. eCollection 2025.
2
Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.微小残留病与多发性骨髓瘤患者更好的生存结果的关联:一项荟萃分析。
JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.
3
New criteria for response assessment: role of minimal residual disease in multiple myeloma.
反应评估的新标准:微小残留病在多发性骨髓瘤中的作用。
Blood. 2015 May 14;125(20):3059-68. doi: 10.1182/blood-2014-11-568907. Epub 2015 Apr 2.
4
Treatment-related symptom management in patients with multiple myeloma: a review.多发性骨髓瘤患者的治疗相关症状管理:综述
Support Care Cancer. 2015 May;23(5):1431-45. doi: 10.1007/s00520-014-2552-1. Epub 2015 Feb 3.
5
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.深度测序方法对多发性骨髓瘤微小残留病灶检测的预后价值。
Blood. 2014 May 15;123(20):3073-9. doi: 10.1182/blood-2014-01-550020. Epub 2014 Mar 19.